Evidence map›Paper›PMID 37680308›Full record

ArticleAmerican journal of ophthalmology case reports2023

Linezolid toxic optic neuropathy: A case report and review of visual prognosis.

Kevin J Toolan, Jacob Fondriest, Kaitlin Keenan, Thomas Mizen, Milena Stosic

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of ophthalmology case reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Kevin J ToolanDepartment of Ophthalmology, Rush University, Chicago, IL, USA.
Jacob FondriestDepartment of Ophthalmology, Rush University, Chicago, IL, USA.
Kaitlin KeenanDepartment of Neurological Sciences Faculty and Staff, Rush University, Chicago, IL, USA.
Thomas MizenDepartment of Ophthalmology, Rush University, Chicago, IL, USA.
Milena StosicDepartment of Neurological Sciences Faculty and Staff, Rush University, Chicago, IL, USA.
Rush University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To describe a case of linezolid toxic optic neuropathy in a 71-year-old female and review the relevant literature. Observations: An adult female with progressive, symmetric vision loss was hypothesized to have linezolid toxic optic neuropathy. Following cessation of linezolid, the patient experienced improvement in visual function over two months. Conclusions and importance: Patients diagnosed with linezolid toxic optic neuropathy can expect some return of visual function after cessation. The degree of return does not correlate to the cumulative dose of the drug. The goal of this study was to summarize and add to the current body of literature on the topic.

Indexed as

LinezolidNon-organic visual disordersOcular toxicityOptic nerveToxic optic neuropathy

Identifiers

PMID37680308
PMCPMC10480323
OpenAlexW4386189918

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.